Large Cell Lung Lung carcinoma is the most common cause of cancer deaths throughout the world, responsible for more deaths alone than caused by breast, colon, and prostate cancer combined each year. Non-small cell lung cancer (NSCLC) makes up 85% of the cases. Historically, large-cell lung carcinoma (LCLC) was classified as a rare and aggressive subtype of non-small cell lung cancer (NSCLC), accounting for roughly 3–9% of cases.[1]
These statistics have changed over the past few decades, though. Latest diagnostic techniques like immunohistochemistry and advanced molecular profiling are able to help classify most LCLC cases into more specific subtypes of NSCLC (adenocarcinoma or squamous cell carcinoma).[2] Only the undifferentiated tumors that do not have any specific markers are now classified as an actual LCLC, so they make up even more of a minority. Despite being so rare, the tumor is often too advanced by the time it’s detected, so early diagnosis is critical.
Clinically, LCLC is often managed on the same guidelines as NSCLC. However, according to the molecular profile, we can use extremely specific and targeted therapies for a large-cell tumor.[3]
WHO Definition: Large Cell Lung
According to its WHO definition, large-cell carcinoma is an undifferentiated NSCLC that lacks any morphological and immunohistochemical (IHC) differentiation toward squamous, glandular (adenocarcinoma), or any other specific lineage.[4] It is a diagnosis of exclusion, assigned when no non-small cell subtype can be identified reliably.
Epidemiology & Risk Factors
NSCLC is the most common form of lung cancer and accounts for approximately 85% of all lung cancers. Although adenocarcinoma is the most common subtype, LCLC is a rare histologic subtype but a subset of clinical significance.
Population-based research studies from before advanced diagnostics show that the percentage of total lung cancer cases attributable to large cell cancer likely ranges from 3–9% and the estimated incidence rate is approximately 1.4 cases of large cell lung cancer per 100,000 individuals annually. With new diagnostics, pure LCLC has become much less common (<1% of NSCLCs)[5], but still causes a disproportionately high mortality burden, in part because it typically follows an aggressive clinical course and low survival probability.
- Most cases occur in patients over 60 years old
- Slight male predominance with a male-to-female ratio of 1.5:1
- Prevalence rates vary globally, reflecting differences in smoking rates, occupational exposures, and environmental pollution
What Causes Large Cell Carcinoma?
The development of large cell carcinoma, like other lung cancers, is driven by a combination of environmental exposures and genetic changes that lead to malignant transformation. The risk factors are also mostly shared across NSCLC subtypes.
1. Cigarette/Tobacco Smoking: Remains the single most important risk factor. Heavy, long-term smokers (>20 pack-years) face a markedly higher risk.[6]
2. Occupational and Environmental Exposures: Several workplace and environmental factors significantly increase risk: asbestos, radon, silica dust, diesel exhaust, heavy metals (arsenic, chromium, nickel), and polycyclic aromatic hydrocarbons. Asbestos exposure creates up to a 50-fold risk when combined with smoking.
3. Carcinogens such as polycyclic aromatic hydrocarbons and nitrosamines induce mutations in tumor suppressor genes (e.g., TP53) and oncogenes (e.g., KRAS).
4. Genetic mutations in genes such as TP53, KRAS, and EGFR have been seen in LCLC cases, but less frequently than in other NSCLC subtypes.
5. Patients with pre-existing lung diseases, COPD, fibrosis, and tuberculosis have an increased risk of lung cancer. It appears that chronic inflammation and longstanding inefficient mucociliary clearance lead to lung carcinogenesis.
6. Diets low in antioxidants, physical inactivity, and comorbidities like diabetes may increase susceptibility.
Pathophysiology
LCLC arises from epithelial cells of the lung but lacks the defining features of adenocarcinoma, squamous cell carcinoma, or small-cell carcinoma.
The pathophysiology involves a complex sequence of molecular events leading to the malignant transformation of bronchial epithelial cells. The process typically begins with exposure to carcinogens, most commonly tobacco smoke components, which induce DNA damage and mutations in critical regulatory genes. Unlike other subtypes, LCLC demonstrates a unique pattern of genetic changes:
- Loss of cellular differentiation markers
- Acquisition of aggressive growth characteristics
- Stronger resistance to apoptosis
Molecular Pathways:7Guo, J., Ma, Y., Lin, J., Jiang, G., He, J., Lu, H., Wu, W., Diao, X., Fan, Q., Wu, C., Liu, J., Fu, D., & Hou, L. (2023). Whole-exome and targeted gene sequencing of large-cell lung carcinoma reveals recurrent mutations in the PI3K pathway. British Journal of Cancer, 129(2), 366-373. https://doi.org/10.1038/s41416-023-02301-2
- TP53 mutations: impaired DNA repair and genomic instability.
- KRAS mutations: Activation of MAPK signaling, causing uncontrolled cellular proliferation and resistance to apoptosis, associated with smoking history.
- EGFR/ALK/ROS1 mutations: promote tumor growth and angiogenesis. The EGFR mutation is seen particularly in non-smokers
- PD-L1 overexpression: Present in many cases, supporting the use of immunotherapy.
Histological Features of Large Cell Carcinoma
The histological features of LCLC are quite distinct compared to even the other NSCLC subtypes:
- Sheets of large, polygonal cells with abundant cytoplasm[7]
- Cell size is around 50-100 μm in diameter
- Large nuclei with prominent nucleoli
- Marked pleomorphism (cells varying in size and shape) and high mitotic activity
Histological patterns of large cell carcinoma (LCC). (A) Classical LCC showing large cells with visible nucleoli and low nuclear–cytoplasmic ratio, lacking neuroendocrine features (B, C). LCC with neuroendocrine morphology showing organoid nesting, palisading, rosettes, frequent mitoses, large cells with fine chromatin and prominent nucleoli (D). Immunohistochemistry for chromogranin A: positive staining limited to large cell neuroendocrine carcinoma. (Image Courtesy: Massoni Neto, L. M., Bianchi, C. P., Ab’Saber, A. M., Parra, E. R., Takagaki, T., Pereira, J. C., Soares, F. A., Leite, K., & Capelozzi, V. L.. (2007). p53 immunostaining is correlated with reduced survival and is not correlated with gene mutations in resected pulmonary large cell carcinomas.Brazilian Journal of Medical and Biological Research,40(8), 1045–1053. https://doi.org/10.1590/S0100-879X2006005000122. Available fromResearch Gate. Licenced under CC by 4.0)
Histological Subtypes:
The current WHO classification has narrowed down the category of large cell carcinoma. Most former subtypes have been reclassified based on their features.[8]
1. Large Cell Carcinoma: core diagnosis. It refers to an undifferentiated NSCLC that lacks any microscopic or immunohistochemical evidence of squamous, glandular, or other specific differentiation. This was formerly called “Classic LCLC”.
2. Large-cell Neuroendocrine Carcinoma (LCNEC): It is now classified as a separate, high-grade neuroendocrine tumor, not as a variant of large-cell carcinoma. It is biologically aggressive and has features that overlap with small-cell lung cancer.
3. Other Variants:
- The basaloid variant is now considered a subtype of squamous cell carcinoma.
- Clear Cell variant is not a standalone diagnosis; clear cells can be seen in other types like adenocarcinoma.
- Lymphoepithelioma-like carcinoma is very rare, often associated with Epstein-Barr virus (EBV) infection
Large Cell Carcinoma vs Small Cell Carcinoma
Although large-cell lung carcinoma (LCLC) and small-cell lung carcinoma (SCLC) are both high-grade lung cancers, they differ in biology, clinical presentation, and treatment.
| Feature | Large-Cell Lung Carcinoma (LCLC) | Small cells with scant cytoplasm, finely granular chromatin, and nuclear molding |
|---|---|---|
| Cell Morphology | Large polygonal cells with abundant cytoplasm, prominent nucleoli, and poorly differentiated | Extremely rapid growth, central tumors, and early metastasis |
| Histologic Definition | Diagnosis of exclusion (lacks adenocarcinoma, squamous, or neuroendocrine differentiation) | Defined by neuroendocrine differentiation and high mitotic rate |
| Growth & Spread | Rapid growth, often peripheral tumors | Primarily systemic chemotherapy ± radiotherapy; surgery is rare |
| Paraneoplastic Syndromes | Rare | Common |
| Treatment | Managed like NSCLC: surgery (if early), chemotherapy, targeted therapy, immunotherapy | TP53 and RB1 loss is nearly universal |
| Molecular Features | KRAS, TP53 mutations; occasionally EGFR/ALK | TP53 and RB1 loss nearly universal |
| Prognosis | Poor, but slightly better if detected early; 5-year survival <20% overall | Very poor, median survival 12–18 months for limited stage, <1 year if extensive stage |
Clinical Presentation (Symptoms & Signs)
Symptoms:
LCLC shares many presenting symptoms with other lung cancers. The clinical presentation often includes both local and systemic manifestations.
Respiratory Symptoms
- Persistent cough, often productive, and sometimes with hemoptysis
- Dyspnea
- Chest pain
- Hoarseness resulting from recurrent laryngeal nerve involvement
Systemic Symptoms
- Unexplained weight loss
- Fatigue and loss of appetite
- Low-grade fever
- Night sweats
Physical Examination Findings:
- Decreased breath sounds over affected areas
- Dullness to percussion (pleural effusion or consolidation)
- Fixed, enlarged lymph nodes (supraclavicular)
- Signs of superior vena cava obstruction in advanced cases
- Digital clubbing (less common than in other lung cancers)
Differential Diagnosis:
| Tumor Type | Key Features | Immunohistochemistry (IHC) |
|---|---|---|
| Adenocarcinoma | Glandular differentiation | TTF-1, napsin A positive |
| Squamous cell carcinoma | Keratinization, intercellular bridges | p40, CK5/6 positive |
| Small-cell carcinoma | Small round cells, nuclear molding | Chromogranin, synaptophysin positive |
| Large-cell neuroendocrine carcinoma | Large cells + neuroendocrine morphology | Synaptophysin, chromogranin positive |
| LCLC | Undifferentiated large cells, no squamous/glandular features | Negative for TTF-1, napsin A, p40 |
Diagnosis of Large-cell Lung Carcinoma
Because LCLC is a diagnosis of exclusion, thorough investigation is essential to differentiate it from adenocarcinoma, squamous carcinoma, and small-cell carcinoma. The pathologist’s diagnostic workflow should include a panel of IHC stains to seek lineage markers (for example, TTF-1 and napsin A for adenocarcinoma; p40/p63 and CK5/6 for squamous carcinoma; chromogranin/synaptophysin/CD56 for neuroendocrine differentiation). If lineage markers are absent and morphology remains undifferentiated, LCLC may be diagnosed. When possible, tissue should be sent for comprehensive molecular testing (NGS) and PD-L1 testing.
Clinical Evaluation:
- The first step is to collect enough information about the patient’s medical and exposure history:
Initial Imaging Studies:
- A chest X-ray is often the initial imaging study of choice, but chest X-rays have limited sensitivity for early-stage disease. They may show nonspecific findings such as:
- High-Resolution Computed Tomography (HRCT) (gold standard): CT of the chest with intravenous contrast is the gold standard for LCLC diagnosis. Large-cell carcinomas typically appear as:
Advanced Imaging:
- Positron Emission Tomography-CT (PET-CT) is crucial for staging and treatment planning, showing:
- Brain MRI is routinely performed due to a high propensity for brain metastases:
CT scans showing different lung pathologies: (a) adenocarcinoma, often peripheral and sometimes large or ground-glass in appearance; (b) large-cell carcinoma, typically a rapidly growing peripheral mass with irregular margins; (c) squamous cell carcinoma, usually central and sometimes cavitating; (d) normal lung for comparison.(Image Courtesy: Uddin, J. (2024). Attention-Based DenseNet for Lung Cancer Classification Using CT Scan and Histopathological Images.Designs,8(2), 27. https://doi.org/10.3390/designs8020027. Available fromMDPI. Licenced under CC by 4.0)
Tissue Diagnosis:
- Biopsy options (based on tumor location):
Immunohistochemistry (IHC):
The IHC profile helps confirm LCLC diagnosis:
- Negative markers: TTF-1, napsin A, p63, CK5/6, chromogranin, synaptophysin, CD56
- Positive markers: CK7, pan-cytokeratin (sometimes focal staining for others)
Molecular Testing:
While targetable mutations are less common in LCLC, testing includes:
- EGFR mutations
- ALK rearrangements
- ROS1 fusions
- PD-L1 expression (for immunotherapy eligibility)
- Extended testing (NGS panels): Identifies rare mutations, trial eligibility, and prognostic markers
LCLC Staging
LCLC is staged using the TNM (Tumor, Node, Metastasis) system developed by the American Joint Committee on Cancer (AJCC). Staging is through PET-CT and brain MRI, and accurate staging is critical for treatment decisions.
TNM: T (tumor size and invasion), N (nodal involvement), M (metastasis)
- Stage I → Tumor confined to the lung, no nodal involvement
- Stage II → Larger tumor or spread to nearby lymph nodes
- Stage III → Local spread to mediastinal lymph nodes or adjacent structures
- Stage IV → Distant metastases (common sites: brain, bones, liver, adrenal glands)
LCLC Treatment & Management
The therapy choice depends primarily on tumor stage, molecular/P-DL1 profile, patient comorbidities, and performance status.[9]
Therapeutic management options for NSCLC (Image Courtesy: Crintea, A., Constantin, A., Motofelea, A. C., Crivii, C., Velescu, M. A., Coșeriu, R. L., Ilyés, T., Crăciun, A. M., & Silaghi, C. N. (2023). Targeted EGFR Nanotherapy in Non-Small Cell Lung Cancer.Journal of Functional Biomaterials,14(9), 466. https://doi.org/10.3390/jfb14090466. Available fromMDPI. Licenced under CC by 4.0)
Surgical Resection:
Surgery offers the strongest chance of cure, but only for patients diagnosed early. Unfortunately, most LCLC patients get diagnosed at a very late stage, where surgery is not recommended. An ideal patient for surgery should have the following characteristics:
- Resectable disease (Stage I-IIIA)
- Good pulmonary reserve so that the patient will be able to survive surgery
- There should be no distant metastases
Regarding surgical procedure, lobectomy is the standard, however, segmentectomy or wedge resection can be a choice in patients with limited pulmonary reserve. Extended resections (pneumonectomy) or even VATS can also be an option.
Adjuvant & Neoadjuvant Therapy:
Even when tumors are surgically resectable, treatment does not end there.
- Adjuvant chemotherapy (usually platinum-based combination) has clear benefit in the postoperative setting to lower recurrence rates, particularly in stage II and III.
- Neoadjuvant (preoperative) therapy with chemotherapy or more commonly chemoradiotherapy to decrease the bulk of disease in patients with locally advanced but resectable disease.
Radiation Therapy:
For patients who cannot undergo surgery, whether due to medical reasons or personal choice, radiation becomes the main choice.
- Stereotactic body radiotherapy (SBRT) is preferred for small, early-stage disease in patients who can’t have surgery. It constitutes a high-dose radiation delivered in 1-5 fractions.[10]
- Concurrent chemoradiotherapy is the standard treatment for locally advanced disease: It combines radiation with platinum-based chemotherapy and requires careful dose sculpting around critical anatomical structures.
Systemic Chemotherapy:
Platinum-based doublet combinations are the first-line treatment for advanced/unresectable LCLC. The usual combinations are: cisplatin or carboplatin with paclitaxel, gemcitabine, vinorelbine, or docetaxel.
Precision Medicine & Targeted Therapy:
One of the biggest shifts in lung cancer treatment has been molecular profiling. While actionable mutations are less common in LCLC compared to adenocarcinoma, testing is still recommended. While less common than in adenocarcinoma, molecular testing may identify actionable mutations in some LCLC tumors. In fact, testing for these markers is now standard in NSCLC, including LCLC.
- EGFR mutations: Treated with erlotinib or gefitinib
- ALK rearrangements: Targeted with crizotinib or newer ALK inhibitors
- ROS1 fusions: Responsive to crizotinib
- Other targets: Identified through comprehensive molecular profiling
Immunotherapy:
- Checkpoint inhibitors (e.g., pembrolizumab, nivolumab, atezolizumab) boost the immune system’s ability to recognize and attack cancer.
- PD-L1 testing guides eligibility: Pembrolizumab is especially effective in patients with high PD-L1 expression (≥50%).[11]
- Combination regimens of chemotherapy + immunotherapy are becoming more common in advanced disease, improving survival more than what either approach could achieve alone.
Palliative Care:
- Palliative radiotherapy helps relieve pain from bone or brain metastases.
- Symptom management: Dyspnea, cough, hemoptysis, and pain control.
- Nutritional and psychosocial support
Complications
- Superior vena cava syndrome, pleural effusion, airway obstruction, and recurrent laryngeal nerve palsy.
- Metastatic complications: Brain, bone, liver involvement
- Paraneoplastic syndromes: Cushing’s syndrome, Lambert-Eaton myasthenic syndrome, peripheral neuropathies, and venous thromboembolism.
- Treatment-related toxicities: chemotherapy myelosuppression, pneumonitis, colitis, endocrinopathies, and postoperative infections.
Prognosis
LCLC carries a poorer prognosis than other NSCLC subtypes.
5-year prognosis and survival rates for the different stages of Large Cell Lung Carcinoma (LCLC) at the time of diagnosis
Conclusion
Large-cell lung carcinoma may be an uncommon diagnosis, but its aggressiveness demands attention equal to, if not greater than, more prevalent NSCLC subtypes. While its classification has narrowed due to modern pathology, the remaining “true” LCLCs are challenging, undifferentiated tumors.
Accurate subtyping and molecular/PD-L1 testing are essential because they directly dictate therapy. Stage remains the most important prognostic factor; surgery remains the cornerstone for early disease, while systemic therapy, personalized with targeted agents and immunotherapy, is central in advanced disease management. Ultimately, continued efforts in smoking cessation and adherence to screening guidelines offer the best hope for reducing the mortality of this formidable disease.
References
[1] Weinberger, S. E., Cockrill, B. A., & Mandel, J. (2019). 20 – Lung Cancer: Etiologic and Pathologic Aspects. In S. E. Weinberger, B. A. Cockrill, & J. Mandel (Eds.),Principles of Pulmonary Medicine (Seventh Edition)(pp. 259–269). Elsevier. https://doi.org/10.1016/B978-0-323-52371-4.00023-4
[2] Suster, D. I., & Mino-Kenudson, M. (2020). Molecular Pathology of Primary Non-small Cell Lung Cancer.Archives of Medical Research,51(8), 784-798. https://doi.org/10.1016/j.arcmed.2020.08.004
[3] Imyanitov, E. N., Iyevleva, A. G., & Levchenko, E. V. (2020). Molecular testing and targeted therapy for non-small cell lung cancer: Current status and perspectives.Critical Reviews in Oncology/Hematology,157, 103194. https://doi.org/10.1016/j.critrevonc.2020.103194
[4] WHO Classification of Tumours Editorial Board.WHO Classification of Tumours: Thoracic Tumours. 5th ed.; International Agency for Research on Cancer; 2021.
[5] Singh, G., Singh, A., & Dave, R. (2023). An Update on WHO Classification of Thoracic Tumours 2021- Newly Described Entities and Terminologies.JOURNAL OF CLINICAL AND DIAGNOSTIC RESEARCH. https://doi.org/10.7860/JCDR/2023/62583.18076
[6] Pleasants, R. A., Rivera, M. P., Tilley, S. L., & Bhatt, S. P. (2020). Both Duration and Pack-Years of Tobacco Smoking Should Be Used for Clinical Practice and Research.Annals of the American Thoracic Society,17(7), 804. https://doi.org/10.1513/AnnalsATS.202002-133VP
[7] Guo, J., Ma, Y., Lin, J., Jiang, G., He, J., Lu, H., Wu, W., Diao, X., Fan, Q., Wu, C., Liu, J., Fu, D., & Hou, L. (2023). Whole-exome and targeted gene sequencing of large-cell lung carcinoma reveals recurrent mutations in the PI3K pathway.British Journal of Cancer,129(2), 366-373. https://doi.org/10.1038/s41416-023-02301-2
[8] Rajdev, K., Siddiqui, A. H., Ibrahim, U., Patibandla, P., Khan, T., & El-Sayegh, D. (2018). An Unusually Aggressive Large Cell Carcinoma of the Lung: Undiagnosed until Autopsy. Cureus, 10(2), e2202. https://doi.org/10.7759/cureus.2202
[9] Nicholson, A. G., Tsao, M. S., Beasley, M. B., et al. (2022). The 2021 WHO Classification of Lung Tumors: Impact of Advances Since 2015.Journal of Thoracic Oncology, 17(3), 362-387.
[10] Ettinger DS, Wood DE, Aisner DL, et al. Non–Small Cell Lung Cancer, Version 3.2022, NCCN Clinical Practice Guidelines in Oncology.J Natl Compr Canc Netw. 2022;20(5):497-530.
[11] Tsang M. W. (2016). Stereotactic body radiotherapy: current strategies and future development. Journal of thoracic disease, 8(Suppl 6), S517–S527. https://doi.org/10.21037/jtd.2016.03.14
[12] Kim, H., & Chung, J. H. (2019). PD-L1 Testing in Non-small Cell Lung Cancer: Past, Present, and Future. Journal of pathology and translational medicine, 53(4), 199–206. https://doi.org/10.4132/jptm.2019.04.24